Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder
Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh
Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh
View: Text | PDF
Research Article Metabolism Neuroscience

Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder

  • Text
  • PDF
Abstract

Accumulation of lysosomal storage material and late-stage neurodegeneration are hallmarks of lysosomal storage disorders (LSDs) affecting the brain. Yet, for most LSDs, including CLN3 disease, the most common form of childhood dementia, it is unclear what mechanisms drive neurologic symptoms. Do deficits arise from loss of function of the mutated protein or toxicity from storage accumulation? Here, using in vitro voltage-sensitive dye imaging and in vivo electrophysiology, we find progressive hippocampal dysfunction occurs before notable lysosomal storage and neuronal loss in 2 CLN3 disease mouse models. Pharmacologic reversal of lysosomal storage deposition in young mice does not rescue this circuit dysfunction. Additionally, we find that CLN3 disease mice lose an electrophysiologic marker of new memory encoding — hippocampal sharp-wave ripples. This discovery, which is also seen in Alzheimer’s disease, suggests the possibility of a shared electrophysiologic signature of dementia. Overall, our data describe new insights into previously unknown network-level changes occurring in LSDs affecting the central nervous system and highlight the need for new therapeutic interventions targeting early circuit defects.

Authors

Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh

×

Figure 1

Activation of the DG after PP stimulation is significantly decreased in CLN3–/– mice by 2 months of age.

Options: View larger image (or click on image) Download as PowerPoint
Activation of the DG after PP stimulation is significantly decreased in ...
(A–I) Raster plots of average fluorescence change (ΔF/F; warm colors, excitation; cool colors, inhibition) over time (x axis) and location within the hippocampus (y axis). PP stimulation location indicated by star. (A) Stimulation of the PP in 2-month-old animals reveals robust excitation of the DG in WT mice. (B) CLN3–/– DG is hypoexcitable as compared with WT after PP stimulation. (C) WT vs. CLN3–/– rasters were compared using a permutation sampling method. Pixels with P > 0.05 are masked in gray. For regions of significance with P < 0.05, the difference in fluorescence change (ΔF/FWT – ΔF/FCLN3KO) is shown. (D–F) The CLN3–/– DG continues to be hypoexcitable at 6–7 months and (G–I) 18–21 months. (J) Quantification of total fluorescence change in the entire DG supports hypoexcitability in CLN3–/– mice (2-way ANOVA, followed by Tukey’s multiple-comparisons test). (K) Peak fluorescence is also decreased in CLN3–/– mice (1-way ANOVA, followed by Holm-Šídák multiple-comparisons test). (L) Signal propagation is slowed in the 2-month-old CLN3–/– DG, as measured by time to peak response in regions of interest moving from the stimulation site to the distal end of the DG (2-way ANOVA). (M and N) The magnitude and slope of the extracellular field response recorded during VSD experiments in 6-month-old WT and CLN3–/– DG supports hypoexcitability in CLN3–/– DG (1-way ANOVA, followed by Holm-Šídák multiple-comparisons test). For all panels: *P < 0.05, **P < 0.01. Group sizes (n = slices, N = mice): 2-month WT n = 24, N = 6; 2-month CLN3–/– n = 26, N = 5; 6- to 7-month WT n = 23, N = 5; 6- to 7-month CLN3–/– n = 30, N = 8; 18- to 21-month WT n = 25, N = 7; 18- to 21-month CLN3 n = 26, N = 7. For all graphs mean ± SEM shown.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts